FindTrial
Sign In

SD-809

DRUG6 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., Auspex Pharmaceuticals, Inc.

Conditions

ChoreaChorea Associated With Huntington DiseaseTOURETTE SYNDROMETardive Dyskinesia

Phase 1

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)
CompletedNCT02674321
Auspex Pharmaceuticals, Inc.TOURETTE SYNDROME
Start: 2014-07-31End: 2015-06-30Updated: 2021-11-09

Phase 2

Aim to Reduce Movements in Tardive Dyskinesia
CompletedNCT02195700
Auspex Pharmaceuticals, Inc.Tardive Dyskinesia
Start: 2014-06-30End: 2015-05-31Updated: 2021-11-09

Phase 3

First Time Use of SD-809 in Huntington Disease
CompletedNCT01795859
Teva Branded Pharmaceutical Products R&D, Inc.Chorea
Start: 2013-08-05End: 2014-12-05Updated: 2017-09-20
Alternatives for Reducing Chorea in Huntington Disease
CompletedNCT01897896
Auspex Pharmaceuticals, Inc.Chorea Associated With Huntington Disease
Start: 2013-11-12End: 2017-08-21Updated: 2021-11-09
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
CompletedNCT02198794
Auspex Pharmaceuticals, Inc.Tardive Dyskinesia
Start: 2014-10-20End: 2020-12-14Updated: 2022-04-01
Addressing Involuntary Movements in Tardive Dyskinesia
CompletedNCT02291861
Auspex Pharmaceuticals, Inc.Tardive Dyskinesia
Start: 2014-10-31End: 2016-08-19Updated: 2026-06-23

Related Papers

Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease
CNS Drugs2025-01-182 citations
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use
Journal of Clinical Psychopharmacology2024-06-20
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
2024-04-012 citations
Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study
Movement Disorders Clinical Practice2023-07-2911 citations
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
2022-10-1524 citations
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
Journal of Neurology Neurosurgery & Psychiatry2019-07-1047 citations
Huntington’s Disease Clinical Trials Corner: August 2018
Journal of Huntington s Disease2018-06-0131 citations
Huntington’s Disease Clinical Trials Corner: February 2018
2018-01-0144 citations
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
2017-06-28125 citations
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
Journal of Clinical Movement Disorders2017-02-1596 citations
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease
JAMA2016-07-05391 citations